How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
NCT ID: NCT01790984
Last Updated: 2021-05-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
27 participants
INTERVENTIONAL
2009-04-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake
NCT01399632
Lipoprotein Turnover on Low- and High-MUFA Portfolio Diets
NCT00430430
Effects of Meal Macronutrients on Postprandial Lipids
NCT07313787
Effect of High-carbohydrate or High-monounsaturated Fat on Blood Pressure: Meta-analysis of Randomized Clinical Trials
NCT02626325
Optimal Dietary Fat Pattern to Prevent Cardiovascular Disease Among Type 2 Diabetes
NCT00467168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High sugar low starch diet
A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with low sugar to starch content, with foods containing a high sugar to starch content to reach a target ratio of starch to sugar of 1:1.2
High sugar low starch diet
Low sugar high starch diet
Low sugar high starch diet
A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with a high sugar to starch content, with foods containing a low sugar to starch content to reach a target ratio of starch to sugar of 5:1
High sugar low starch diet
Low sugar high starch diet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High sugar low starch diet
Low sugar high starch diet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Increased cardio-metabolic risk ('RISCK' criteria Jebb et al (2010) Am J Clin Nutr 92, 748-758).
* Apo E3E3 genotype
Exclusion Criteria
* Diabetes
* Smoker
* Excessive alcohol consumption (\>27units/week)
* Medication likely to affect lipid metabolism
* \>3kg weight loss in preceding 3 months
* Any medical condition (eg. GI tract, allergies) affecting lipid metabolism or ability to comply with dietary interventions
* Involvement in any other study
18 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
University of Cambridge
OTHER
Bruce A. Griffin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bruce A. Griffin
Professor of Nutritional Metabolism
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruce A Griffin, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Surrey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Surrey
Guildford, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BB/G009899/1
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
RN0172 A/B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.